HYFTOR
Clinical safety rating: caution
Comprehensive clinical and safety monograph for HYFTOR (HYFTOR).
HYFTOR (solithromycin) is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking peptide bond formation and inhibiting translation. It also exhibits anti-inflammatory effects by modulating cytokine production and neutrophil activity.
| Metabolism | Primarily hepatic via CYP3A4; also metabolized by CYP2J2 and to a minor extent by other CYP enzymes. Main metabolite is solithromycin-M1, which is active. |
| Excretion | Primarily hepatic metabolism; minimal renal excretion (<1% as unchanged drug). Eliminated via feces (84%) and urine (4%) as metabolites. |
| Half-life | Terminal elimination half-life is approximately 5.5 hours (range: 3.2–9.1 h), supporting twice-daily dosing. |
| Protein binding | 99.5% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Apparent volume of distribution is 8.2 L/kg, indicating extensive tissue distribution and accumulation in skin. |
| Bioavailability | Topical bioavailability is approximately 1.5% of applied dose systematically absorbed; no oral bioavailability data (not intended for systemic use). |
| Onset of Action | Onset occurs within 1–2 hours after topical application; maximal effect by 4–8 hours. |
| Duration of Action | Duration of action is approximately 12 hours, consistent with twice-daily application. Clinical improvement sustained with regular use. |
| Molecular Weight | 444.56 |
0.5% gel, apply a thin layer to the treatment area once daily at bedtime. Duration: 4-8 weeks.
| Dosage form | GEL |
| Renal impairment | No dose adjustment required based on GFR. Topical application results in minimal systemic absorption. |
| Liver impairment | No dose adjustment required for Child-Pugh class A, B, or C. Minimal systemic absorption. |
| Pediatric use | Safety and efficacy in pediatric patients have not been established. Not recommended for use in patients <18 years. |
| Geriatric use | No specific dose adjustments. Use with caution due to potential for increased skin fragility in elderly; apply sparingly. |
| 1st trimester | No adequate human studies; animal studies show teratogenicity at high doses; use only if benefit outweighs risk. |
| 2nd trimester | No adequate human studies; avoid use due to potential fetal risk. |
| 3rd trimester | No adequate human studies; avoid use near term due to risk of neonatal hypoglycemia. |
Clinical note
Comprehensive clinical and safety monograph for HYFTOR (HYFTOR).
| Placental transfer | Crosses placenta in animals; human data lacking. |
| Breastfeeding | Excreted in animal milk; not recommended during breastfeeding due to potential for serious adverse effects in the infant. |
| Lactation Rating |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Hypersensitivity to HYFTORPregnancyBreastfeeding
| Precautions | Hepatotoxicity (elevated liver enzymes, hepatitis), QT interval prolongation (avoid in patients with known QTc prolongation or concurrent use with drugs that prolong QT), Hypersensitivity reactions (including anaphylaxis), Clostridioides difficile-associated diarrhea (CDAD), Potential for drug interactions with CYP3A4 substrates (e.g., statins, oral contraceptives), Avoid use in patients with myasthenia gravis (may exacerbate weakness) |
| Food/Dietary | No clinically significant food interactions. |
| Clinical Pearls |
Loading safety data…
| L5 (Contraindicated) |
| Teratogenic Risk | HYFTOR (an hypothetical drug) has not been studied in pregnant women. In animal reproduction studies, administration during organogenesis resulted in embryolethality and fetal malformations at maternal doses less than the maximum recommended human dose. There is a risk of teratogenicity throughout all trimesters, especially during the first trimester. Avoid use during pregnancy unless the potential benefit justifies the potential risk to the fetus. |
| Fetal Monitoring | If HYFTOR is used during pregnancy, perform fetal ultrasound to assess for structural anomalies. Monitor maternal liver function tests and complete blood counts regularly. Consider serum drug level monitoring if available. |
| Fertility Effects | Based on animal studies, HYFTOR may impair fertility in males and females. In humans, decreased sperm count and motility have been reported. Female patients may experience menstrual irregularities and reduced ovarian reserve. Contraception is recommended during treatment and for 6 months after cessation. |
| HYFTOR (halobetasol propionate) is a super-high-potency topical corticosteroid. Do not use on face, groin, or axillae due to risk of skin atrophy. Limit use to 2 weeks and total dose to 50 g/week to minimize systemic absorption. Occlusion increases penetration and side effects. Avoid abrupt discontinuation to prevent rebound flare. |
| Patient Advice | Apply a thin layer only to affected areas, do not cover with bandages or dressings unless directed. · Do not use on face, groin, or underarms. · Use for no more than 2 weeks at a time; stop if condition clears earlier. · Avoid contact with eyes and mucous membranes. · Do not use for other skin conditions or on large areas of broken skin. · Wash hands after application unless treating hands. · Inform your doctor if you develop skin thinning, increased redness, or signs of infection. · Do not stop abruptly; follow tapering instructions from your doctor. |